U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H12N2O.C4H6O6
Molecular Weight 326.3019
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of COTININE TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1[C@@H](CCC1=O)C2=CN=CC=C2

InChI

InChIKey=NNGHNRKZQZZELM-NDAAPVSOSA-N
InChI=1S/C10H12N2O.C4H6O6/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8;5-1(3(7)8)2(6)4(9)10/h2-3,6-7,9H,4-5H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t9-;1-,2-/m01/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C10H12N2O
Molecular Weight 176.2151
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://cancercontrol.cancer.gov/brp/tcrb/monographs/7/m7_7.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26972290

Cotinine is a product formed after the chemical nicotine enters the body. Measuring cotinine in people’s blood is the most reliable way to determine exposure to nicotine for both smokers and nonsmokers exposed to environmental tobacco smoke. Cotinine is safe, non-addictive and has pharmacokinetic properties adequate for therapeutic use. Research has shown that cotinine has antipsychotic, anxiolytic, and antidepressant properties and modulates the serotonergic, cholinergic and dopaminergic systems. Cotinine behaves as a positive allosteric modulator of the nicotinic acetylcholine receptors and has anti-inflammatory effects. Cotinine is under investigation as an agent for the treatment of depression, PTSD, schizophrenia, Alzheimer's disease and Parkinson's disease.

CNS Activity

Curator's Comment: Known to be CNS penetrant in mouse. Human data not available.

Originator

Sources: DOI: 10.1002/cber.18930260165

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Nicotinic acetylcholine receptors alpha3/alpha6/beta2 (Saimiri sciureus)
236.0 µM [EC50]
Target ID: Nicotinic acetylcholine receptors alpha4/beta2 (Saimiri sciureus)
495.0 µM [EC50]
175.0 µM [IC50]
Conditions
PubMed

PubMed

TitleDatePubMed
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
2000 Oct
The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age.
2001
Accuracy of self-reported cigarette smoking among pregnant women in the 1990s.
2001 Apr
Infant exposure to environmental tobacco smoke: a prevalence study in Australia.
2001 Apr
Cigarette smoking, salivary/gingival crevicular fluid cotinine and periodontal status. A 10-year longitudinal study.
2001 Apr
Smoking status, reading level, and knowledge of tobacco effects among low-income pregnant women.
2001 Apr
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.
2001 Apr 12
Factors associated with discrepancies between self-reports on cigarette smoking and measured serum cotinine levels among persons aged 17 years or older: Third National Health and Nutrition Examination Survey, 1988-1994.
2001 Apr 15
Novel liquid chromatographic-tandem mass spectrometric methods using silica columns and aqueous-organic mobile phases for quantitative analysis of polar ionic analytes in biological fluids.
2001 Apr 25
Osteogenic protein-1 overcomes the inhibitory effect of nicotine on posterolateral lumbar fusion.
2001 Aug 1
Smoking reduction in smokers compliant to a smoking cessation trial with nicotine patch.
2001 Feb
Two behavioral treatments for smoking reduction: a pilot study.
2001 Feb
Determinants of environmental tobacco smoke in a population of Puerto Rican children.
2001 Feb
Postpartum smoking behaviors and immune response in mothers of term and preterm infants.
2001 Feb
[Smoking in adolescents, saliva cotinine concentrations and respiratory disease].
2001 Feb
Reference interval and subject variation in excretion of urinary metabolites of nicotine from non-smoking healthy subjects in Denmark.
2001 Feb
Assessing the impact of a nurse-led health education intervention for people with peripheral vascular disease who smoke: the use of physiological markers, nicotine dependence and withdrawal.
2001 Feb
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.
2001 Feb
Tobacco hypersensitivity and environmental tobacco smoke exposure in a pediatric population.
2001 Jan
Evaluation of the effect of passive smoking on otitis media in children by an objective method: urinary cotinine analysis.
2001 Jan
Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey.
2001 Jan
Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking.
2001 Jan
Counselor and stimulus control enhancements of a stage-matched expert system intervention for smokers in a managed care setting.
2001 Jan
Acute effects of cigarette smoking on platelet-dependent thrombin generation.
2001 Jan
Does passive smoking increase the frequency of health service contacts in children with asthma?
2001 Jan
Effects of nicotine and cotinine on porcine arterial endothelial cell function.
2001 Jan
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.
2001 Jan 3
High-performance liquid chromatographic determination of pyridostigmine bromide, nicotine, and their metabolites in rat plasma and urine.
2001 Jul
Trends in the smoking habits of young adults with diabetes.
2001 Jul
Prevalence of nicotine consumption in drug deaths.
2001 Jul 15
The effect of tobacco smoke, nicotine, and cotinine on the mutagenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).
2001 Jul 25
Nicotine produces selective degeneration in the medial habenula and fasciculus retroflexus.
2001 Jul 6
Quantification of nicotine, chlorpyrifos and their metabolites in rat plasma and urine using high-performance liquid chromatography.
2001 Jun 15
A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women.
2001 Jun 15
Exposure to ethanol and nicotine during the brain growth spurt: spatial DMP performance in male rats.
2001 Mar
Nicotine metabolism and CYP2D6 phenotype in smokers.
2001 Mar
The effect of stopping smoking on cervical Langerhans' cells and lymphocytes.
2001 Mar
Nicotine and cotinine adducts of a melanin intermediate demonstrated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
2001 Mar
Environmental tobacco smoke and serum vitamin C levels in children.
2001 Mar
Red wine polyphenols, in the absence of alcohol, reduce lipid peroxidative stress in smoking subjects.
2001 Mar 15
Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes.
2001 May
CDC unveils body burden.
2001 May
Adaptation of an enzyme immunoassay to assess urinary cotinine in nonsmokers exposed to tobacco smoke.
2001 May
Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2'-(14)C]nicotine.
2001 May
Measures of maternal tobacco exposure and infant birth weight at term.
2001 May 15
Drop in cotinine levels signals less smoke exposure, experts say.
2001 May 2
Bacterial mutagenicity of some tobacco aromatic nitrogen bases and their mixtures.
2001 May 31
In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation.
2001 May 4
Systemic nicotine exposure in tobacco harvesters.
2001 May-Jun
Personal exposures to PM(2.5) and polycyclic aromatic hydrocarbons and their relationship to environmental tobacco smoke at two locations in Greece.
2001 May-Jun
Patents

Sample Use Guides

Mouse: 5 mg/kg during 37 days
Route of Administration: Oral
In Vitro Use Guide
High (190 ug/ml) concentration of Cotinine significantly altered all the sperm kinetic variables in relation to the time of incubation (forward motility, velocity, linearity and beat cross-frequency). Despite the impact seen on these parameters, there was still 30% forward motility after 24 h of incubation.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:50:50 GMT 2023
Edited
by admin
on Fri Dec 15 15:50:50 GMT 2023
Record UNII
FQ7X51Z02G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COTININE TARTRATE
Common Name English
COTININE, TARTRATE
Common Name English
2-PYRROLIDINONE, 1-METHYL-5-(3-PYRIDINYL)-, (S)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)
Systematic Name English
2-PYRROLIDINONE, 1-METHYL-5-(3-PYRIDINYL)-, (S)-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (1:1)
Common Name English
Code System Code Type Description
CAS
4315-41-7
Created by admin on Fri Dec 15 15:50:50 GMT 2023 , Edited by admin on Fri Dec 15 15:50:50 GMT 2023
PRIMARY
FDA UNII
FQ7X51Z02G
Created by admin on Fri Dec 15 15:50:50 GMT 2023 , Edited by admin on Fri Dec 15 15:50:50 GMT 2023
PRIMARY
PUBCHEM
91826822
Created by admin on Fri Dec 15 15:50:50 GMT 2023 , Edited by admin on Fri Dec 15 15:50:50 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY